Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma.

Yoon SS, Stangenberg L, Lee YJ, Rothrock C, Dreyfuss JM, Baek KH, Waterman PR, Nielsen GP, Weissleder R, Mahmood U, Park PJ, Jacks T, Dodd RD, Fisher CJ, Ryeom S, Kirsch DG.

Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1207-16. doi: 10.1016/j.ijrobp.2009.02.052. Erratum in: Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1607.

2.

Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.

Tanaka Y, Shibata MA, Morimoto J, Otsuki Y.

Anticancer Res. 2011 Apr;31(4):1225-34.

PMID:
21508369
3.

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.

Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.

Clin Cancer Res. 2009 May 15;15(10):3384-95. doi: 10.1158/1078-0432.CCR-08-2170. Epub 2009 May 5.

4.

The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.

Ning S, Laird D, Cherrington JM, Knox SJ.

Radiat Res. 2002 Jan;157(1):45-51.

PMID:
11754641
5.

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.

Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D.

Mol Cancer Ther. 2006 Jul;5(7):1774-82.

6.

Imaging biomarker dynamics in an intracranial murine glioma study of radiation and antiangiogenic therapy.

Chung C, Jalali S, Foltz W, Burrell K, Wildgoose P, Lindsay P, Graves C, Camphausen K, Milosevic M, Jaffray D, Zadeh G, Ménard C.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):805-12. doi: 10.1016/j.ijrobp.2012.07.005. Epub 2012 Aug 26.

PMID:
22929856
7.

Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.

Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.

Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893.

9.

SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.

Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X, Moss KG, Louie SG, Mendel DB, Cherrington JM.

FASEB J. 2002 May;16(7):681-90.

PMID:
11978732
11.

Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.

Huynh H, Ngo VC, Choo SP, Poon D, Koong HN, Thng CH, Toh HC, Zheng L, Ong LC, Jin Y, Song IC, Chang AP, Ong HS, Chung AY, Chow PK, Soo KC.

Curr Cancer Drug Targets. 2009 Sep;9(6):738-47.

PMID:
19754358
12.

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.

Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB.

Mol Cancer Ther. 2006 May;5(5):1280-9.

13.

Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03).

Jakob J, Simeonova A, Kasper B, Ronellenfitsch U, Rauch G, Wenz F, Hohenberger P.

Radiat Oncol. 2016 Jun 3;11:77. doi: 10.1186/s13014-016-0654-2.

14.

Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma.

Jakob J, Simeonova A, Kasper B, Ronellenfitsch U, Wenz F, Hohenberger P.

Ann Surg Oncol. 2015 Sep;22(9):2839-45. doi: 10.1245/s10434-015-4680-3. Epub 2015 Jun 18.

PMID:
26085221
15.

Combining targeted agents with modern radiotherapy in soft tissue sarcomas.

Wong P, Houghton P, Kirsch DG, Finkelstein SE, Monjazeb AM, Xu-Welliver M, Dicker AP, Ahmed M, Vikram B, Teicher BA, Coleman CN, Machtay M, Curran WJ, Wang D.

J Natl Cancer Inst. 2014 Oct 18;106(11). pii: dju329. doi: 10.1093/jnci/dju329. Print 2014 Nov. Review.

16.

Necrosis of a skin autograft after short-term treatment with sunitinib in a 14-year-old girl with metastatic alveolar soft part sarcoma of the thigh.

Hanzer M, Nebl A, Spendel S, Pilhatsch A, Urban C, Benesch M.

Klin Padiatr. 2010 May;222(3):184-6. doi: 10.1055/s-0030-1249093. Epub 2010 May 31.

PMID:
20514624
18.

Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.

Ren W, Korchin B, Lahat G, Wei C, Bolshakov S, Nguyen T, Merritt W, Dicker A, Lazar A, Sood A, Pollock RE, Lev D.

Clin Cancer Res. 2008 Sep 1;14(17):5466-75. doi: 10.1158/1078-0432.CCR-08-0562.

19.

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.

Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP.

Urol Oncol. 2009 Jul-Aug;27(4):391-9. doi: 10.1016/j.urolonc.2008.03.017. Epub 2008 Jun 4.

PMID:
18534874
20.

Sunitinib: from rational design to clinical efficacy.

Chow LQ, Eckhardt SG.

J Clin Oncol. 2007 Mar 1;25(7):884-96. Review.

PMID:
17327610

Supplemental Content

Support Center